CN104302639B - 作为c型肝炎病毒抑制剂的哌嗪‑哌啶化合物 - Google Patents

作为c型肝炎病毒抑制剂的哌嗪‑哌啶化合物 Download PDF

Info

Publication number
CN104302639B
CN104302639B CN201380021717.8A CN201380021717A CN104302639B CN 104302639 B CN104302639 B CN 104302639B CN 201380021717 A CN201380021717 A CN 201380021717A CN 104302639 B CN104302639 B CN 104302639B
Authority
CN
China
Prior art keywords
alkyl
compound
methyl
mmol
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201380021717.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN104302639A (zh
Inventor
丹尼尔·D·朗
罗伯特·默里·麦金内尔
洛里·琼·范奥登
加文·奥加瓦
唐纳·威尔顿
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Theravance Biopharma R&D IP LLC
Original Assignee
Theravance Biopharma R&D IP LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Biopharma R&D IP LLC filed Critical Theravance Biopharma R&D IP LLC
Publication of CN104302639A publication Critical patent/CN104302639A/zh
Application granted granted Critical
Publication of CN104302639B publication Critical patent/CN104302639B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
CN201380021717.8A 2012-04-25 2013-04-24 作为c型肝炎病毒抑制剂的哌嗪‑哌啶化合物 Expired - Fee Related CN104302639B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261637959P 2012-04-25 2012-04-25
US61/637,959 2012-04-25
US201361774033P 2013-03-07 2013-03-07
US61/774,033 2013-03-07
PCT/US2013/037920 WO2013163262A1 (en) 2012-04-25 2013-04-24 Piperazine-piperidine compounds as hepatitis c virus inhibitors

Publications (2)

Publication Number Publication Date
CN104302639A CN104302639A (zh) 2015-01-21
CN104302639B true CN104302639B (zh) 2017-03-29

Family

ID=48237291

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380021717.8A Expired - Fee Related CN104302639B (zh) 2012-04-25 2013-04-24 作为c型肝炎病毒抑制剂的哌嗪‑哌啶化合物

Country Status (17)

Country Link
US (1) US9206159B2 (cg-RX-API-DMAC7.html)
EP (1) EP2850075B1 (cg-RX-API-DMAC7.html)
JP (1) JP6069491B2 (cg-RX-API-DMAC7.html)
CN (1) CN104302639B (cg-RX-API-DMAC7.html)
CA (1) CA2869640C (cg-RX-API-DMAC7.html)
CY (1) CY1118920T1 (cg-RX-API-DMAC7.html)
DK (1) DK2850075T3 (cg-RX-API-DMAC7.html)
ES (1) ES2624846T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20170471T1 (cg-RX-API-DMAC7.html)
HU (1) HUE032173T2 (cg-RX-API-DMAC7.html)
LT (1) LT2850075T (cg-RX-API-DMAC7.html)
ME (1) ME02682B (cg-RX-API-DMAC7.html)
PL (1) PL2850075T3 (cg-RX-API-DMAC7.html)
PT (1) PT2850075T (cg-RX-API-DMAC7.html)
RS (1) RS55864B1 (cg-RX-API-DMAC7.html)
SI (1) SI2850075T1 (cg-RX-API-DMAC7.html)
WO (1) WO2013163262A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108794454B (zh) * 2017-04-27 2023-08-15 广东东阳光药业股份有限公司 一种咪唑环化合物的制备方法
CN112480084B (zh) * 2017-11-27 2021-09-21 常州寅盛药业有限公司 反应路线简单的达卡他韦起始原料的合成方法
EP4759807A1 (en) 2023-08-11 2026-06-17 Shenzhen Zhongge Biological Technology Co., Ltd. Proteolysis targeting chimera compound for degrading irak4 and use thereof
CN122497677A (zh) 2023-10-20 2026-07-31 奇树医药公司 一种降解irak4的蛋白降解靶向嵌合体化合物及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110064695A1 (en) * 2009-09-11 2011-03-17 Yao-Ling Qiu Hepatitis c virus inhibitors
WO2012061552A1 (en) * 2010-11-04 2012-05-10 Theravance, Inc. Novel inhibitors of hepatitis c virus

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007115805A2 (en) * 2006-04-05 2007-10-18 European Molecular Biology Laboratory (Embl) Aurora kinase inhibitors
US8329159B2 (en) 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8303944B2 (en) 2006-08-11 2012-11-06 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7659270B2 (en) 2006-08-11 2010-02-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8147818B2 (en) 2008-02-13 2012-04-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20120040977A1 (en) 2009-02-23 2012-02-16 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
WO2010094977A1 (en) 2009-02-23 2010-08-26 Arrow Therapeutics Limited Novel biphenyl compounds useful for the treatment of hepatitis c
US8796466B2 (en) 2009-03-30 2014-08-05 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
SG176015A1 (en) 2009-05-13 2011-12-29 Gilead Sciences Inc Antiviral compounds
EP2473056A4 (en) 2009-09-04 2013-02-13 Glaxosmithkline Llc CHEMICAL COMPOUNDS
WO2011031904A1 (en) 2009-09-11 2011-03-17 Enanta Pharmaceuticals, Inc Hepatitis c virus inhibitors
EP2475254A4 (en) * 2009-09-11 2013-05-22 Enanta Pharm Inc HEPATITIS C-VIRUS HEMMER
US20110274648A1 (en) 2009-11-11 2011-11-10 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US8653070B2 (en) 2009-12-14 2014-02-18 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8377980B2 (en) 2009-12-16 2013-02-19 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN102883718A (zh) 2009-12-24 2013-01-16 顶点制药公司 用于治疗或预防黄病毒感染的类似物
WO2011091446A1 (en) 2010-01-22 2011-07-28 Glaxosmithkline Llc Chemical compounds
MA34147B1 (fr) 2010-03-09 2013-04-03 Merck Sharp & Dohme Composes tricycliques fusionnes de silyle et leurs methodes d'utilisation dans le cadre du traitement de maladies virales
EP2575819A4 (en) 2010-06-04 2013-11-27 Enanta Pharm Inc INHIBITORS OF HEPATITIS C VIRUS
US20120195857A1 (en) 2010-08-12 2012-08-02 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
WO2012048421A1 (en) 2010-10-14 2012-04-19 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor compounds
US8552047B2 (en) 2011-02-07 2013-10-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
AR088630A1 (es) 2011-11-03 2014-06-25 Theravance Inc Inhibidores del virus de la hepatitis c
CA2869908C (en) * 2012-04-25 2018-02-20 Theravance Biopharma R&D Ip, Llc Hepatitis c virus inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110064695A1 (en) * 2009-09-11 2011-03-17 Yao-Ling Qiu Hepatitis c virus inhibitors
WO2012061552A1 (en) * 2010-11-04 2012-05-10 Theravance, Inc. Novel inhibitors of hepatitis c virus

Also Published As

Publication number Publication date
ES2624846T3 (es) 2017-07-17
ME02682B (me) 2017-06-20
CA2869640A1 (en) 2013-10-31
SI2850075T1 (sl) 2017-06-30
WO2013163262A1 (en) 2013-10-31
HUE032173T2 (en) 2017-09-28
EP2850075B1 (en) 2017-02-22
CA2869640C (en) 2018-03-20
DK2850075T3 (en) 2017-05-22
CN104302639A (zh) 2015-01-21
JP6069491B2 (ja) 2017-02-01
US20130287730A1 (en) 2013-10-31
CY1118920T1 (el) 2018-01-10
PT2850075T (pt) 2017-05-02
HRP20170471T1 (hr) 2017-06-02
EP2850075A1 (en) 2015-03-25
PL2850075T3 (pl) 2017-08-31
JP2015514807A (ja) 2015-05-21
LT2850075T (lt) 2017-05-10
US9206159B2 (en) 2015-12-08
RS55864B1 (sr) 2017-08-31

Similar Documents

Publication Publication Date Title
CN103946220B (zh) 含有片段{2‑[4‑(联苯‑4‑基)‑1h‑咪唑‑2‑基]吡咯烷‑1‑羰基甲基}胺的杆状丙型肝炎病毒抑制剂
CN103189371B (zh) 丙型肝炎病毒抑制剂
US9206159B2 (en) Piperazine-piperidine compounds as hepatitis C virus inhibitors
US8883135B2 (en) Crystalline form of a pyridyl-piperazinyl hepatitis C virus inhibitor
US9365549B2 (en) Hepatitis C virus inhibitors

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20170329

Termination date: 20180424